<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254513</url>
  </required_header>
  <id_info>
    <org_study_id>GERICO10/0910 (GetugP03)</org_study_id>
    <nct_id>NCT01254513</nct_id>
  </id_info>
  <brief_title>Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients</brief_title>
  <acronym>GERICO10</acronym>
  <official_title>Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (&gt;=75), &quot;Vulnerable&quot; or &quot;Frail&quot; , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the feasibility of two different chemotherapy&#xD;
      protocols with adjusted doses for patients aged 75 and over who often have medical problems&#xD;
      other than prostate cancer. Patient will receive Docetaxel either every 3 weeks or weekly. In&#xD;
      both cases, chemotherapy is combined with prednisone. The protocol will be considered&#xD;
      feasible when patient will receive 6 cycles of chemotherapy (1 cycle = 3 weeks).&#xD;
&#xD;
      Additionally to this primary objective, efficacy will also be evaluated for both protocols as&#xD;
      well as tolerance to treatment, quality of life and evolution of geriatric data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard management of castration-resistant metastatic prostate cancer is represented by&#xD;
      chemotherapy with Docetaxel 75 mg/m² every 3 weeks combined with Prednisone since a&#xD;
      symptomatic and overall survival benefit was demonstrated.&#xD;
&#xD;
      Although this benefit is independent of age in the study by Tannock (cut-off:69), it does not&#xD;
      seem possible to extrapolate these results, obtained in a selected population, to the&#xD;
      majority of patients we encounter in daily practice, &gt;= 75 years old and / or unfit.&#xD;
&#xD;
      Retrospective studies have shown that chemotherapy was feasible, at standard or adapted doses&#xD;
      in an unselected elderly population with good results in terms of tolerance and efficacy over&#xD;
      symptoms.&#xD;
&#xD;
      Our study aims to evaluate prospectively the feasibility of a chemotherapy with&#xD;
      Docetaxel/Prednisone administered every 3 weeks (60 mg / m² at D1C1 then 70 mg / m² at D1 for&#xD;
      subsequent cycles if tolerance is good) or weekly (35mg / m² at D1 and D8 with Day 1 = Day&#xD;
      21) to patients &gt;= 75 years old, evaluated by comprehensive geriatric assessment, belonging&#xD;
      to group 2 &quot;vulnerable&quot; or to group 3 &quot;frail&quot; of the classification proposed by the&#xD;
      International Society of Geriatric Oncology (SIOG).&#xD;
&#xD;
      Feasibility is defined as the possibility for a patient to receive 6 cycles of chemotherapy&#xD;
      without withdrawal. Reasons for study withdrawal were defined by the GERICO Group and are the&#xD;
      followings:&#xD;
&#xD;
        -  stop or delay of chemotherapy &gt; 2 weeks&#xD;
&#xD;
        -  Necessity to reduce the dose of chemotherapy &gt; 25 %&#xD;
&#xD;
        -  febrile neutropenia or non-haematological grade 3 toxicity (except alopecia) according&#xD;
           to NCI-CTCAE V4.0.&#xD;
&#xD;
        -  Geriatric criterion (Activity of Daily Living (ADL) decrease &gt;= 2 points)&#xD;
&#xD;
      The statistical methodology used is a double randomized phase II after stratification&#xD;
      according to the SIOG criteria, based on a Simon Optimum plan.&#xD;
&#xD;
      A pharmacokinetic / pharmacodynamic study is associated to our project, based on a method of&#xD;
      population pharmacokinetic. The aim is to highlight predictors of the haematological&#xD;
      tolerance of this chemotherapy by evaluating clinical, geriatric and biological parameters.&#xD;
&#xD;
      The results of this study will support the terms of prescription of chemotherapy, in patients&#xD;
      aged 75 and over, classified as &quot;vulnerable&quot; or &quot;frail&quot; regarding SIOG criteria, with defined&#xD;
      geriatric assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2010</start_date>
  <completion_date type="Actual">April 27, 2017</completion_date>
  <primary_completion_date type="Actual">May 10, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of 2 different protocols of Docetaxel chemotherapy</measure>
    <time_frame>Up to 18 weeks (6 cycles of chemotherapy)</time_frame>
    <description>Main criteria is the rate of patients receiving 6 cycles of treatment without experiencing any of the following criteria:&#xD;
Stop or delay of chemotherapy &gt; 2 weeks&#xD;
Necessity to reduce the dose of chemotherapy &gt; 25 %&#xD;
Febrile neutropenia or non-haematological grade 3 toxicity (except alopecia)according to NCI-CTCAE V4.0&#xD;
Geriatric criterion ( ADL decrease &gt;= 2 points)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization until death for any cause or last follow-up news (censored data)</time_frame>
    <description>Overall Survival is defined as the time from randomization until death for any cause or last follow-up news (censored data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric evaluation</measure>
    <time_frame>At baseline, D1 of Cycle 1 and Cycle 4, at the end of treatment and at follow-up visits</time_frame>
    <description>The impact of the chemotherapy will be evaluated on Comprehensive Geriatric Assessment :&#xD;
Test de screening G8&#xD;
Cumulative Illness Rating Scale(CIRSG)&#xD;
Folstein Mini Mental State (MMS)&#xD;
Activity of Daily Living (ADL)&#xD;
Instrumental Activity of Daily Living (IADL)&#xD;
Geriatric Depression Scale (GDS)&#xD;
Mini Nutritionnal Assessment (MNA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits</time_frame>
    <description>Tolerance and safety will be assessed through recording of adverse events using NCI-CTCAE toxicity classification V4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>At baseline, D1 of the Cycle 4, at the end of the treatment and at the follow-up visits</time_frame>
    <description>The impact of the chemotherapy is evaluated on the European Organisation for Research and Treatment of Cancer (EORTC) Quality Of Life - Questionnaire - QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs measurement</measure>
    <time_frame>At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits</time_frame>
    <description>Tolerance and safety will be assessed through vital signs measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-specific antigen (PSA) measurements</measure>
    <time_frame>At baseline, D1 of each cycle , at the end of treatment and at the follow-up visits</time_frame>
    <description>Efficacy will be assessed through monitoring PSA values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A - Docetaxel every 3 weeks + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks&#xD;
Prednisone 10 mg/day continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Docetaxel weekly + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)&#xD;
Prednisone 10 mg/day continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel every 3 weeks + Prednisone</intervention_name>
    <description>Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks&#xD;
Prednisone 10 mg/day continuously</description>
    <arm_group_label>Arm A - Docetaxel every 3 weeks + Prednisone</arm_group_label>
    <other_name>TAXOTERE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel weekly+ Prednisone</intervention_name>
    <description>Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)&#xD;
Prednisone 10 mg/day continuously</description>
    <arm_group_label>Arm A - Docetaxel every 3 weeks + Prednisone</arm_group_label>
    <arm_group_label>Arm B - Docetaxel weekly + Prednisone</arm_group_label>
    <other_name>TAXOTERE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 75&#xD;
&#xD;
          -  Histologically proven prostate adenocarcinoma&#xD;
&#xD;
          -  Metastatic disease, not pre-treated with chemotherapy refractory to castration&#xD;
&#xD;
          -  Hormone refractory prostate cancer is defined as follows:&#xD;
&#xD;
               -  Patients with documented testosterone castration (&lt;0.50 ng / ml)&#xD;
&#xD;
               -  Patient who received prior hormonal therapy (either orchidectomy or Luteinizing&#xD;
                  hormone-releasing hormone (LHRH) agonist alone or combined with an anti-androgen)&#xD;
&#xD;
               -  Patients should continue primary androgen suppression by LHRH agonist (in case of&#xD;
                  non-surgical castration)&#xD;
&#xD;
               -  For patients treated with anti-androgens prior to inclusion, a wash-out period is&#xD;
                  required (4 weeks for flutamide and nilutamide, 6 weeks for other products) as&#xD;
                  well as measured progression after anti-androgen discontinuation.&#xD;
&#xD;
          -  Progressive disease under hormonotherapy, with progression defined by&#xD;
&#xD;
        Increase of PSA level (two consecutive increases of PSA compared to baseline with a minimum&#xD;
        of one week between both measurements)&#xD;
&#xD;
        OR emergence of a new lesion&#xD;
&#xD;
        OR measurable progressive disease (increase of a previous measurable lesion &gt;= 25% in cross&#xD;
        section)&#xD;
&#xD;
        OR progressive bone metastases (defined only by the appearance of a new lesion on bone&#xD;
        scan)&#xD;
&#xD;
        OR progressive symptoms (defined as cancer pain Grade 2 according to the NCI-CTC V4.0,&#xD;
        despite level 2 analgesics intake).&#xD;
&#xD;
          -  Patients of Groups 2 and 3 [ &quot;vulnerable&quot; and &quot;frail&quot;] of SIOG classification&#xD;
&#xD;
          -  WHO Performance Status (PS) &gt;= 3&#xD;
&#xD;
          -  PSA &gt;= 5 ng / ml&#xD;
&#xD;
          -  Neutrophils &gt;= 2.109 /L&#xD;
&#xD;
          -  Platelets &gt;= 100.109/L&#xD;
&#xD;
          -  Haemoglobin ≥ 9 g/dl&#xD;
&#xD;
          -  Bilirubin and SGOT / SGPT &lt;1.5 x ULN (&lt;= 2.5 x ULN if hepatic metastasis)&#xD;
&#xD;
          -  creatinine &lt;= 2.5 x ULN&#xD;
&#xD;
          -  In case of previous palliative or analgesic radiotherapy, a minimum of 14 days must&#xD;
             have elapsed between end of radiotherapy and inclusion into the study&#xD;
&#xD;
          -  Previous treatment with bisphosphonates should be continued without change during the&#xD;
             study treatment and can not be initiated either within 28 days prior to study entry or&#xD;
             during the study&#xD;
&#xD;
          -  Signed informed consent by patients, according to local regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &quot;healthy&quot; or &quot;terminal illness&quot; Groups according to the recommendations of&#xD;
             International Society of Geriatric Oncology (SIOG)&#xD;
&#xD;
          -  Concomitant or previous malignancy within 5 years prior the study (except basal or&#xD;
             squamous in situ cell skin carcinoma)&#xD;
&#xD;
          -  Presence of brain metastasis symptoms&#xD;
&#xD;
          -  Prior treatment by intravenous radiopharmaceutical agent (e.g. Strontium 89, Samarium&#xD;
             lexidronam) within 2 months before study entry&#xD;
&#xD;
          -  Initiation of a bisphosphonate therapy within 28 days prior to randomisation&#xD;
&#xD;
          -  Any concomitant anticancer treatment (radiotherapy, radiopharmaceutical agent,&#xD;
             chemotherapy)&#xD;
&#xD;
          -  Patients with uncontrolled infection&#xD;
&#xD;
          -  Patients with peripheral neuropathy of grade&gt; 1&#xD;
&#xD;
          -  Patients medically unstable (e.g. unstable diabetes, uncontrolled hypertension or&#xD;
             decompensated heart failure or myocardial infarct within 3 months)&#xD;
&#xD;
          -  Gastro duodenal active ulcer&#xD;
&#xD;
          -  Hypersensitivity to study drugs&#xD;
&#xD;
          -  Treatment with any experimental drug within 30 days prior to or during the study&#xD;
&#xD;
          -  Psychological, familial, sociological or geographical location conditions which do not&#xD;
             allow medical monitoring and compliance with study protocol.&#xD;
&#xD;
          -  Patients protected by the law or patients placed under protective supervision of&#xD;
             adults&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loic Mourey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Annemasse-Bonneville</name>
      <address>
        <city>Ambilly</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal</name>
      <address>
        <city>Castres</city>
        <zip>81108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Chambery</name>
      <address>
        <city>Chambery</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Marguerite</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Hartmann</name>
      <address>
        <city>Levallois-perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nimes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie/Claudius Regaud</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Region D'Annecy</name>
      <address>
        <city>Pringy Cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Périgueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Centre Rene Huguenin</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico - Centre Rene Gauducheau</name>
      <address>
        <city>Saint-herblain Cedex</city>
        <zip>44885</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon-les-bains</city>
        <zip>74200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Du Parc</name>
      <address>
        <city>Toulouse</city>
        <zip>31078</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean du Languedoc</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Prostate cancer</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>Vulnerable and Frail (SIOG classification)</keyword>
  <keyword>castration-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

